November 17th, afternoon，2024 China Biomedical Front-Runners 100 ListYu 22024 China Pharmaceutical Industry Development Conference · Shanghai International Biomedical Industry Week Series Events —— Biomedical Industry Investment and Financing Forum Released.METiS PharmaceuticalsSelected for ""Top 100 Leaders in China's Biomedical Industry" List。
METiS TechBio, founded and led by Dr. Hongmin Chen, a member of the US National Academy of Engineering, along with MIT’s top scientists Dr. Caida Lai and Dr. Wenshou Wang, aims to combine cutting-edge technologies such as AI, machine learning, and quantitative simulations with drug development. This approach drives the more efficient and precise research of innovative drugs, enabling advanced design of innovative delivery materials, selection of drug candidates, formulation design, development of "programmable nucleic acid drugs," and nucleic acid delivery systems. METiS TechBio is committed to bringing revolutionary medicines to patients worldwide, addressing unmet clinical needs.As one of the world's leading drug delivery platforms, METiS TechBio, in the absence of open-source datasets and delivery-related algorithms, started from scratch to innovatively develop groundbreaking artificial intelligence and computational simulation algorithms for the generation and design of ionizable lipids as well as the design and simulation of LNP nanomaterials. Combined with world-leading high-throughput experimental techniques and animal validation platforms, METiS TechBio has established its own data and algorithmic barriers.Moreover, by integrating the rapidly advancing large models and generative AI technologies, METiS TechBio has established the world's firstMETiS LipidLM Lipid Language ModelAndPhatGPT Lipid Generation Model, creating a million-level lipid library and successfully breaking through international patent barriers. At the same time, METiS TechBio combines innovative molecular simulation technology to simulate various microscopic processes of LNP in vivo and in vitro. Relying on a world-class experimental verification platform, it empowers the development of multi-organ targeted nanomaterials, achieving the successful implementation of AI + nanomaterial applications.Currently, China's pharmaceuticals industry is transitioning from an era of "general innovation" to one of "high-quality innovation," with accelerated development in First-in-class and Fast-follow innovations, and the continuous advancement of research pipeline targets. Against this backdrop, METiS TechBio has made the “Top 100 Forerunners in China’s Biomedical Industry” list for two consecutive years, fully demonstrating the company’s innovation, vitality, and growth potential.In the future, METiS TechBio will continue to deepen its core technology platform, empower the pharmaceutical ecosystem through the continuous expansion of AI technology, and actively explore broader application areas. METiS TechBio will remain committed to technology-driven innovation at its core, providing more breakthrough treatment solutions for patients worldwide and promoting high-quality development in the biopharmaceutical industry.Regarding 「Top 100 Leaders in China's Biomedical Industry」The 2024 China Biomedical Front-Runners 100 List is organized by the "2024 China Biomedical Front-Runners (Front-Runners) 100 List Organizing Committee," with the Shanghai Biomedical Science and Technology Industry Promotion Center as the initiating unit. The ecosystem collaboration partners include the Shanghai Biomedical Fund, Shanghai SDIC Pioneer, Qiming Venture Partners, Boyuan Capital, Haitong Securities, Shanghai Frontier, Xinzhe Zhixing Port, and ATLATL Innovation and Research Center. Yiyun Technology serves as the technical support partner, while media partners include Yicai, PharmaCube, R&D Guest, DrugTimes, and Titanium Media, jointly promoting the publication.
Since the release of the list's call for submissions on September 26 until October 31, after extensive mobilization and thorough investigation, 3,500 outstanding enterprises were selected from a database of 35,000 companies. These were further narrowed down to 350 leading enterprises through multiple rounds, including online scoring, expert correspondence evaluation, and offline reviews, ultimately forming a list of 100 companies in each of the biopharmaceuticals, medical devices, and digital healthcare fields.Attachment2024 China Biomedical Leaders 100 List
Scroll images up and down
Learn More About METiS TechBio
